| 9.18 -0.18 (-1.92%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.54 | 1-year : | 13.48 |
| Resists | First : | 9.88 | Second : | 11.54 |
| Pivot price | 9.27 |
|||
| Supports | First : | 8.48 |
Second : | 7.61 |
| MAs | MA(5) : | 8.97 |
MA(20) : | 9.26 |
| MA(100) : | 6.95 |
MA(250) : | 7.07 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.3 |
| %K %D | K(14,3) : | 45.2 |
D(3) : | 32.7 |
| RSI | RSI(14): 55 |
|||
| 52-week | High : | 9.88 | Low : | 4.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TDOC ] has closed above bottom band by 42.5%. Bollinger Bands are 1.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.49 - 9.54 | 9.54 - 9.58 |
| Low: | 9.02 - 9.07 | 9.07 - 9.11 |
| Close: | 9.1 - 9.18 | 9.18 - 9.25 |
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
Thu, 30 Jul 2026
Teladoc Health sinks 21% after mixed quarter and soft outlook (TDOC:NYSE) - Seeking Alpha
Thu, 30 Jul 2026
Teladoc Health, Inc. Stock 12‑Month Price Target Raised to $7.84, Implies 15% Downside - TradingView
Wed, 29 Jul 2026
Teladoc Health, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:TDOC) 2026-07-29 - Seeking Alpha
Wed, 29 Jul 2026
TDOC: Q2 saw strong Integrated Care, a rapid BetterHelp insurance shift, and 2026 guidance lowered - TradingView
Wed, 29 Jul 2026
Is Teladoc Health Inc (TDOC) Overvalued After Q2 Earnings Miss? - GuruFocus
Wed, 29 Jul 2026
Why Teladoc Stock is Getting Crushed Wednesday After Hours - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 181 (M) |
| Shares Float | 179 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 83.6 (%) |
| Shares Short | 28,060 (K) |
| Shares Short P.Month | 29,440 (K) |
| EPS | -0.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.4 |
| Profit Margin | -6.9 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | -3.2 % |
| Return on Equity (ttm) | -12.4 % |
| Qtrly Rev. Growth | -2.5 % |
| Gross Profit (p.s.) | 9.63 |
| Sales Per Share | 13.9 |
| EBITDA (p.s.) | 0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 288 (M) |
| Levered Free Cash Flow | 208 (M) |
| PE Ratio | -9.47 |
| PEG Ratio | 0 |
| Price to Book value | 1.23 |
| Price to Sales | 0.66 |
| Price to Cash Flow | 5.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|